Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Thomas U. Marron"'
Autor:
Petros Fessas, Muntaha Naeem, Matthias Pinter, Thomas U. Marron, David Szafron, Lorenz Balcar, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Musharraf Navaid, Pei-Chang Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Hannah Hildebrand, Yehia I. Abugabal, Tiziana Pressiani, Nicola Personeni, Naoshi Nishida, Masatoshi Kudo, Ahmed Kaseb, Yi-Hsiang Huang, Celina Ang, Anjana Pillai, Lorenza Rimassa, Abdul Rafeh Naqash, Elad Sharon, Alessio Cortellini, David J. Pinato
Publikováno v:
Liver Cancer, Vol 10, Iss 6, Pp 583-592 (2021)
Background and Rationale: Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI therapy can impact immunotherapy efficacy across indicatio
Externí odkaz:
https://doaj.org/article/5b2616ec247c4eb78946d132559d4210
Autor:
Noam D. Beckmann, Phillip H. Comella, Esther Cheng, Lauren Lepow, Aviva G. Beckmann, Scott R. Tyler, Konstantinos Mouskas, Nicole W. Simons, Gabriel E. Hoffman, Nancy J. Francoeur, Diane Marie Del Valle, Gurpawan Kang, Anh Do, Emily Moya, Lillian Wilkins, Jessica Le Berichel, Christie Chang, Robert Marvin, Sharlene Calorossi, Alona Lansky, Laura Walker, Nancy Yi, Alex Yu, Jonathan Chung, Matthew Hartnett, Melody Eaton, Sandra Hatem, Hajra Jamal, Alara Akyatan, Alexandra Tabachnikova, Lora E. Liharska, Liam Cotter, Brian Fennessy, Akhil Vaid, Guillermo Barturen, Hardik Shah, Ying-chih Wang, Shwetha Hara Sridhar, Juan Soto, Swaroop Bose, Kent Madrid, Ethan Ellis, Elyze Merzier, Konstantinos Vlachos, Nataly Fishman, Manying Tin, Melissa Smith, Hui Xie, Manishkumar Patel, Kai Nie, Kimberly Argueta, Jocelyn Harris, Neha Karekar, Craig Batchelor, Jose Lacunza, Mahlet Yishak, Kevin Tuballes, Ieisha Scott, Arvind Kumar, Suraj Jaladanki, Charuta Agashe, Ryan Thompson, Evan Clark, Bojan Losic, Lauren Peters, The Mount Sinai COVID-19 Biobank Team, Panagiotis Roussos, Jun Zhu, Wenhui Wang, Andrew Kasarskis, Benjamin S. Glicksberg, Girish Nadkarni, Dusan Bogunovic, Cordelia Elaiho, Sandeep Gangadharan, George Ofori-Amanfo, Kasey Alesso-Carra, Kenan Onel, Karen M. Wilson, Carmen Argmann, Supinda Bunyavanich, Marta E. Alarcón-Riquelme, Thomas U. Marron, Adeeb Rahman, Seunghee Kim-Schulze, Sacha Gnjatic, Bruce D. Gelb, Miriam Merad, Robert Sebra, Eric E. Schadt, Alexander W. Charney
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Multisystem inflammatory syndrome in children (MIS-C) onsets in COVID-19 patients with manifestations similar to Kawasaki disease (KD). Here the author probe the peripheral blood transcriptome of MIS-C patients to find signatures related to natural k
Externí odkaz:
https://doaj.org/article/7233a40d610f443eac2e6011b12c9368
Autor:
Tomi Jun, Umut Ozbek, Sirish Dharmapuri, Camille Hardy-Abeloos, Huili Zhu, Jung-Yi Lin, Nicola Personeni, Tiziana Pressiani, Naoshi Nishida, Pei-Chang Lee, Chieh-Ju Lee, Hannah Hildebrand, Neil Nimkar, Sonal Paul, Petros Fessas, Muntaha Naeem, Dominik Bettinger, Uqba Khan, Anwaar Saeed, Yi-Hsiang Huang, Masatoshi Kudo, Lorenza Rimassa, Thomas U. Marron, David J. Pinato, Celina Ang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Antibiotic exposure has been associated with worse outcomes with immune checkpoint inhibitors (ICIs) in cancer patients, likely due to disruption of the gut microbiome. Other commonly prescribed medications, such as proton pump inhibitors
Externí odkaz:
https://doaj.org/article/2cd3809960ca4aa790944f7a51d499a1
Autor:
Matthew D. Park, Ivan Reyes-Torres, Jessica LeBerichel, Pauline Hamon, Nelson M. LaMarche, Samarth Hegde, Meriem Belabed, Leanna Troncoso, John A. Grout, Assaf Magen, Etienne Humblin, Achuth Nair, Martina Molgora, Jinchao Hou, Jenna H. Newman, Adam M. Farkas, Andrew M. Leader, Travis Dawson, Darwin D’Souza, Steven Hamel, Alfonso Rodriguez Sanchez-Paulete, Barbara Maier, Nina Bhardwaj, Jerome C. Martin, Alice O. Kamphorst, Ephraim Kenigsberg, Maria Casanova-Acebes, Amir Horowitz, Brian D. Brown, Lucas Ferrari De Andrade, Marco Colonna, Thomas U. Marron, Miriam Merad
Publikováno v:
Nature Immunology. 24:792-801
Autor:
Matthew D. Park, Meriem Belabed, Steven T. Chen, Pauline Hamon, Samarth Hegde, Raphaël Mattiuz, Thomas U. Marron, Miriam Merad
Publikováno v:
Annual Review of Cancer Biology. 7:291-311
Myeloid cells represent a dominant cellular compartment of tumor lesions and play key roles in tumor inception, progression, metastasis, and response to treatment. Mononuclear phagocytes (MNPs), which include dendritic cells and macrophages, are uniq
Autor:
Thomas Talbot, Antonio D'Alessio, Matthias Pinter, Lorenz Balcar, Bernhard Scheiner, Thomas U. Marron, Tomi Jun, Sirish Dharmapuri, Celina Ang, Anwaar Saeed, Hannah Hildebrand, Mahvish Muzaffar, Claudia A. M. Fulgenzi, Suneetha Amara, Abdul Rafeh Naqash, Anuhya Gampa, Anjana Pillai, Yinghong Wang, Uqba Khan, Pei‐Chang Lee, Yi‐Hsiang Huang, Bertram Bengsch, Dominik Bettinger, Yehia I. Mohamed, Ahmed Kaseb, Tiziana Pressiani, Nicola Personeni, Lorenza Rimassa, Naoshi Nishida, Masatoshi Kudo, Arndt Weinmann, Peter R. Galle, Ambreen Muhammed, Alessio Cortellini, Arndt Vogel, David J. Pinato
Publikováno v:
Liver International. 43:695-707
Autor:
Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, Naoshi Nishida, Celina Ang, Thomas U. Marron, Linda Wu, Anwaar Saeed, Brooke Wietharn, Antonella Cammarota, Tiziana Pressiani, Nicola Personeni, Matthias Pinter, Bernhard Scheiner, Lorenz Balcar, Andrea Napolitano, Yi-Hsiang Huang, Samuel Phen, Abdul Rafeh Naqash, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Peter R. Galle, Masatoshi Kudo, Lorenza Rimassa, Amit G. Singal, Rohini Sharma, Alessio Cortellini, Vincent E. Gaillard, Hong Jae Chon, David James Pinato
Publikováno v:
European Journal of Cancer. 175:204-213
IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC).We generated a prospectively maintained database including patients treated with atezolizumab plus
Autor:
Mathew Vithayathil, Antonio D'Alessio, Claudia A. M. Fulgenzi, Naoshi Nishida, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Anwaar Saeed, Brooke Wietharn, Hannah Hildebrand, Linda Wu, Celina Ang, Thomas U. Marron, Arndt Weinmann, Peter R. Galle, Dominik Bettinger, Bertram Bengsch, Arndt Vogel, Lorenz Balcar, Bernhard Scheiner, Pei‐Chang Lee, Yi‐Hsiang Huang, Suneetha Amara, Mahvish Muzaffar, Abdul Rafeh Naqash, Antonella Cammarota, Nicola Personeni, Tiziana Pressiani, Matthias Pinter, Alessio Cortellini, Masatoshi Kudo, Lorenza Rimassa, David J. Pinato, Rohini Sharma
Publikováno v:
Liver International. 42:2538-2547
Background and Aims Combination atezolizumab/bevacizumab is the gold standard for first-line treatment of unresectable hepatocellular carcinoma (HCC). Our study investigated the efficacy and safety of combination therapy in older patients with HCC. M
Autor:
John A. Grout, Philemon Sirven, Andrew M. Leader, Shrisha Maskey, Eglantine Hector, Isabelle Puisieux, Fiona Steffan, Evan Cheng, Navpreet Tung, Mathieu Maurin, Romain Vaineau, Lea Karpf, Martin Plaud, Anne-Laure Begue, Koushik Ganesh, Jérémy Mesple, Maria Casanova-Acebes, Alexandra Tabachnikova, Shilpa Keerthivasan, Alona Lansky, Jessica Le Berichel, Laura Walker, Adeeb H. Rahman, Sacha Gnjatic, Nicolas Girard, Marine Lefevre, Diane Damotte, Julien Adam, Jerome C. Martin, Andrea Wolf, Raja M. Flores, Mary Beth Beasley, Rachana Pradhan, Soren Muller, Thomas U. Marron, Shannon J. Turley, Miriam Merad, Ephraim Kenigsberg, Hélène Salmon
Publikováno v:
Cancer Discovery. 12:2606-2625
It is currently accepted that cancer-associated fibroblasts (CAF) participate in T-cell exclusion from tumor nests. To unbiasedly test this, we used single-cell RNA sequencing coupled with multiplex imaging on a large cohort of lung tumors. We identi
Publikováno v:
Journal of Hepatocellular Carcinoma. 9:571-581
The treatment paradigm for hepatocellular carcinoma (HCC) had been stagnant until recently, with new combinations of targeted and immunotherapies entering the first- and second-line setting for patients with advanced disease. This improvement in ther